Elsevier

Placenta

Volume 35, Supplement, February 2014, Pages S20-S25
Placenta

IFPA Senior Award Lecture: Making sense of pre-eclampsia – Two placental causes of preeclampsia?

https://doi.org/10.1016/j.placenta.2013.12.008Get rights and content

Abstract

Incomplete spiral artery remodelling is the first of two stages of pre-eclampsia, typically of early onset. The second stage comprises dysregulated uteroplacental perfusion and placental oxidative stress. Oxidatively stressed syncytiotrophoblast (STB) over-secretes proteins that perturb maternal angiogenic balance and are considered to be pre-eclampsia biomarkers. We propose that, in addition and more fundamentally, these STB-derived proteins are biomarkers of a cellular (STB) stress response, which typically involves up-regulation of some proteins and down-regulation of others (positive and negative stress proteins respectively). Soluble vascular growth factor receptor-1 (sVEGFR-1) and reduced growth factor (PlGF) then exemplify positive and negative STB stress response proteins in the maternal circulation.

Uncomplicated term pregnancy is associated with increasing sVEGFR-1 and decreasing PlGF, which can be interpreted as evidence of increasing STB stress. STB pathology, at or after term (for example focal STB necrosis) demonstrates this stress, with or without pre-eclampsia. We review the evidence that when placental growth reaches its limits at term, terminal villi become over-crowded with diminished intervillous pore size impeding intervillous perfusion with increasing intervillous hypoxia and STB stress. This type of STB stress has no antecedent pathology, so the fetuses are well-grown, as typifies late onset pre-eclampsia, and prediction is less effective than for the early onset syndrome because STB stress is a late event.

In summary, abnormal placental perfusion and STB stress contribute to the pathogenesis of early and late onset pre-eclampsia. But the former has an extrinsic cause – poor placentation, whereas the latter has an intrinsic cause, ‘microvillous overcrowding’, as placental growth reaches its functional limits. This model explains important features of late pre-eclampsia and raises questions of how antecedent medical risk factors such as chronic hypertension affect early and late sub-types of the syndrome. It also implies that all pregnant women may be destined to get pre-eclampsia but spontaneous or induced delivery averts this outcome in most instances.

Introduction

Pre-eclampsia presents in highly variable ways. The classical sequence is pregnancy induced hypertension (PIH) first and proteinuria second, but the converse sequence occurs in a minority of cases [1]. Its crises, including eclampsia and the HELLP syndrome, may be unheralded, or only partially heralded by pregnancy induced hypertension alone or pregnancy induced proteinuria alone [1]. It is said that pre-eclampsia can only occur after 20 weeks but a well-documented case of eclampsia has been reported at 16 weeks [2]. For a condition that is said to originate in the placenta it is a paradox that severe cases can present suddenly, without warning, after delivery, when the placenta has been removed. A case of eclampsia as long as three weeks after delivery has been described [3].

It is well known that pre-eclampsia is associated with poor placentation and incomplete remodelling of the uteroplacental spiral arteries [4]. However the association is not specific. Poor placentation may occur with fetal growth restriction (FGR) without features of pre-eclampsia [5] or with partial features such as PIH. Poor placentation would be expected to cause FGR. However FGR is not a consistent feature of pre-eclampsia being confined largely to the early onset syndrome. In pre-eclampsia, at or beyond term, neonates are not growth restricted and may even be large for dates [6].

How can we make sense of this apparently inexplicable diversity? In this paper we present new concepts, which may help to address some of the problems.

The placental origins of pre-eclampsia have long been recognised and, after incomplete placentation was described, were formalised in the two stage model of the syndrome [7]. Poor remodelling of the spiral arteries (weeks 8–18 of gestation) leads to ischaemia re-perfusion injury and oxidative stress [8] of the chorionic villi. How the placental problem then extends to become a maternal problem has subsequently become clearer although a full explanation is still lacking.

It was first shown that uncomplicated pregnancy and pre-eclampsia are both associated with a low grade systemic (vascular) inflammatory response, which is more intense in pre-eclampsia. The role of the placenta was explained by the oxidative damage that it sustained. A generalised response to any form of cellular or tissue damage is inflammation [9], a hypothesis, which has been subsequently validated in many different contexts, not associated with pregnancy. In pre-eclampsia the maternal response to the oxidatively damaged placenta is what could have been predicted and what has been found. The precise nature of the stimulus has not been defined because it is not precise. By its very nature oxidative chemical damage may be heterogeneous. The systemic inflammatory response has massive and wide ranging consequences all of which are seen in pre-eclampsia [10]. Hence this model, at the time it was formulated, could explain more features of pre-eclampsia than any other.

Concepts were changed and extended by the later discovery of how angiogenic and antiangiogenic factors of placental origin could contribute to the pre-eclampsia syndrome [11]. This was a crucial development in that it not only specified precise factors secreted by syncytiotrophoblast – soluble vascular growth factor (VEGF) receptor-1 (sVEGFR-1 also known as sFLT1), soluble endoglin (sENG) and placental growth factor (PlGF) – but led to the discovery of potentially useful circulating diagnostic and predictive biomarkers of the syndrome. The typical but by no means consistent pattern (see below) of pre-eclampsia in the circulation is an excess of sVEGFR-1 and sENG, and lower PlGF. This is proposed to deprive endothelium of the support of VEGF, which specifically causes glomerular endotheliosis, a virtually pathognomonic lesion of pre-eclampsia [11]. The discovery was such a major step forward that, for some, it seemed that the problem of pre-eclampsia had been solved.

In this paper we suggest how pre-eclampsia may arise from placental causes other than poor placentation and propose that the angiogenic biomarkers of pre-eclampsia are better considered as markers of an integrated STB stress response.

Section snippets

Oxidative stress, cellular stress and the integrated stress response

The terminology that is used in this section is described in Table 1. In the two stage model oxidative stress is the primary placental problem causing pre-eclampsia. Oxidative stress is one of many forms of cellular stress listed in Table 2. In general, cell stress affects all cellular compartments, in which specific sensors detect the cellular damage rather than the stressful insult itself. Reactive oxygen species are the major second messengers for cellular stress response networks [12]. An

Biomarkers of pre-eclampsia and syncytiotrophoblast stress

Many studies have investigated maternal angiogenic imbalance in relation to syncytial proteins that are secreted during pre-eclampsia, as mentioned above. Soluble VEGFR-1 (sVEGFR-1) and soluble endoglin (sENG) are biomarkers that increase markedly in relation to the disorder. They are not the only ones: others that also increase include leptin, activin-A, CRH (corticotrophin releasing hormone), (reviewed in Ref. [10]), PP13 [26] and PAPP-A [27]. Placental growth factor (PlGF), on the other

Making sense of pre-eclampsia: intrinsic and extrinsic placental causes

Hence there is at least indirect evidence for a mechanism that could dysregulate placental perfusion in mature pregnancies without antecedent poor placentation in early pregnancy. This leads to our hypothesis that there are at least two placental causes of pre-eclampsia: the first is extrinsic to the placenta, affecting the uteroplacental circulation via incomplete spiral artery remodelling; the second is intrinsic with one or more processes associated with the size of the term placenta

Conflict of interest statement

The authors declare that they do not have any conflict of interest.

Acknowledgements

The authors are grateful for help and advice given by Professor T Mayhew, of Nottingham University, U.K.

References (48)

  • A. Ahmed et al.

    Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble VEGFR-1 by oxygen–a review

    Placenta

    (2000)
  • R.M. Gobble et al.

    Differential regulation of human PlGF gene expression in trophoblast and non-trophoblast cells by oxygen tension

    Placenta

    (2009)
  • H. Schneider

    Oxygenation of the placental-fetal unit in humans

    Respir Physiol Neurobiol

    (2011)
  • B. Almog et al.

    Placenta weight percentile curves for singleton and twins deliveries

    Placenta

    (2011)
  • A.B. Caughey et al.

    What is the best measure of maternal complications of term pregnancy: ongoing pregnancies or pregnancies delivered?

    Am J Obstet Gynecol

    (2003)
  • T.M. Mayhew et al.

    Villous trophoblast: morphometric perspectives on growth, differentiation, turnover and deposition of fibrin-type fibrinoid during gestation

    Placenta

    (2001)
  • T.M. Mayhew et al.

    Placental morphogenesis and the star volumes of villous trees and intervillous pores

    Placenta

    (1994)
  • M. Dubiel et al.

    Fetal and placental power Doppler imaging in normal and high-risk pregnancy

    Eur J Ultrasound

    (1999)
  • M. Dubiel et al.

    Computer analysis of three-dimensional power angiography images of foetal cerebral, lung and placental circulation in normal and high-risk pregnancy

    Ultrasound Med Biol

    (2005)
  • R.B. Ness et al.

    Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications

    Am J Obstet Gynecol

    (1996)
  • A.C. Staff et al.

    Review: preeclampsia, acute atherosis of the spiral arteries and future cardiovascular disease: two new hypotheses

    Placenta

    (2013)
  • K.A. Douglas et al.

    Eclampsia in the United Kingdom

    BMJ

    (1994)
  • M.D. Lindheimer et al.

    Eclampsia during the 16th week of gestation

    J Am Med Assoc

    (1974)
  • B. Samuels

    Postpartum eclampsia

    Obstet Gynecol

    (1960)
  • Cited by (346)

    • Preeclampsia epidemiology(ies) and pathophysiology(ies)

      2024, Best Practice and Research: Clinical Obstetrics and Gynaecology
    • Spiral, uterine artery doppler and placental ultrasound in relation to preeclampsia

      2024, Best Practice and Research: Clinical Obstetrics and Gynaecology
    • 10. Role of high dimensional technology in preeclampsia (omics in preeclampsia)

      2024, Best Practice and Research: Clinical Obstetrics and Gynaecology
    • Fetal microchimerism and the two-stage model of preeclampsia

      2023, Journal of Reproductive Immunology
    View all citing articles on Scopus
    View full text